Patents Assigned to Bionomics Limited
  • THERAPEUTIC FORMULATIONS AND USES THEREOF
    Publication number: 20260027057
    Abstract: This invention relates to formulations of compound (I) (BNC2IO), an allosteric modulator of the a7-nicotinic receptor with non-sedative anxiolytic effects; specifically, solid dispersions, methods of manufacture thereof, and therapeutic methods and uses in the treatment of diseases of the central nervous system thereof.
    Type: Application
    Filed: August 6, 2025
    Publication date: January 29, 2026
    Applicant: Bionomics Limited
    Inventors: Dharam Paul, Julia Crossman, Elizabeth Doolin, Tom Reynolds, Xiangming Wu, Jeff Millan, Thomas Stumpfig, Kristie Downing
  • Therapeutic formulations and uses thereof
    Patent number: 12409140
    Abstract: This invention relates to formulations of compound (I) (BNC210), an allosteric modulator of the ?7-nicotinic receptor with non-sedative anxiolytic effects; specifically, solid dispersions, methods of manufacture thereof, and therapeutic methods and uses in the treatment of diseases of the central nervous system thereof.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: September 9, 2025
    Assignee: Bionomics Limited
    Inventors: Dharam Paul, Julia Crossman, Elizabeth Doolin, Tom Reynolds, Xiangming Wu, Jeff Millan, Thomas Stumpfig, Kristie Downing
  • Cyclic compounds as receptor modulating therapeutics and methods and uses thereof
    Patent number: 12275732
    Abstract: The present invention relates generally to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR), such as anxiety, depression and stress related disorders.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: April 15, 2025
    Assignee: Bionomics Limited
    Inventors: Lorna Mitchell, Hamish Toop, Belinda Huff, Justin Ripper, Rajinder Singh, Christophe Morice, Jean-Marie Contreras, Patrick Bazzini, Laurent Schaeffer, Mathieu Michaut
  • Substituted-N-heteroaryl compounds and uses thereof
    Patent number: 12139473
    Abstract: Activators of Kv3.1 and/or Kv3.2 channels which are therapeutically useful in the treatment of cognitive dysfunction and the negative symptoms which are associated with central nervous system disorders such as schizophrenia, Alzheimer's disease, Tourette's syndrome, autism, dementia, epilepsy and other disorders where gamma oscillations are dysfunctional are provided. The activators include substituted N-heteroaryl compounds.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: November 12, 2024
    Assignee: Bionomics Limited
    Inventors: Hamish Toop, Dharam Paul, Rajinder Singh, Erin Smith, Patrick Bazzini, Jean-Marie Contreras, Christophe Morice, Laurent Schaeffer, Celine Michaut-Simon, Florence Chery, Fabrice Garrido
  • Substituted-pyridinyl compounds and uses thereof
    Patent number: 12090146
    Abstract: The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: September 17, 2024
    Assignee: Bionomics Limited
    Inventors: Hamish Toop, Rajinder Singh, Erin Smith, Dharam Paul, Patrick Bazzini, Jean-Marie Contreras, Christophe Morice, Florence Chery, Fabrice Garrido
  • Modulators of ion channel receptors and uses thereof
    Patent number: 11884673
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: January 30, 2024
    Assignee: BIONOMICS LIMITED
    Inventors: Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
  • Antibody and checkpoint inhibitor combination therapy
    Patent number: 11655304
    Abstract: The present invention provides a combination therapy for treatment of a tumour in a subject. The combination therapy comprises administration of (i) an antibody directed against cancer stem cells and (ii) a checkpoint inhibitor.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 23, 2023
    Assignee: Bionomics Limited
    Inventors: Tina Christine Lavranos, Daniel John Inglis, Christopher L. Reyes
  • Modulators of ion channel receptors and uses thereof
    Patent number: 11384085
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: July 12, 2022
    Assignee: BIONOMICS LIMITED
    Inventors: Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
  • Anxiolytic compounds
    Patent number: 10954231
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 23, 2021
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • PHARMACEUTICAL COMBINATION AND USES THEREOF
    Publication number: 20210069147
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • ISOXAZOLYL COMPOUNDS AS RECEPTOR MODULATING COMPOUNDS AND METHODS AND USES THEREOF
    Publication number: 20200392126
    Abstract: The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
    Type: Application
    Filed: November 26, 2018
    Publication date: December 17, 2020
    Applicant: BIONOMICS LIMITED
    Inventors: Justin Anthony RIPPER, Patrick BAZZINI, Jean-Marie CONTRERAS, Nicolas FEICHTER, Christophe MORICE, Laurent SCHAEFFER, Cindy STAHL
  • Method of treating cancer by administering an anti-LGR5 monoclonal antibody
    Patent number: 10745487
    Abstract: The present invention relates generally to the field of cancer biology. Some embodiments of the methods and compositions provided herein relate to administration of humanized antibodies or antigen-binding fragments thereof that specifically bind to LRG5 to treat certain cancers.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Christopher L. Reyes, Peter Chu, Elizabeth Doolin, Jose Iglesias
  • Predictive biomarkers
    Patent number: 10564162
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Predictive baseline biomarkers for use of vascular disrupting agents
    Patent number: 10520508
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 31, 2019
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Anxiolytic compounds
    Patent number: 10233181
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 10213409
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: February 26, 2019
    Assignee: BIONOMICS LIMITED
    Inventors: Jason Hugh Chaplin, Gurmit Sing Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Predicting response to cancer therapy
    Patent number: 10159659
    Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: December 25, 2018
    Assignee: BIONOMICS LIMITED
    Inventor: Jose Iglesias
  • Combination treatment protocol
    Patent number: 10137105
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 27, 2018
    Assignee: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • PREDICTIVE BIOMARKERS
    Publication number: 20180196048
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE